Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by

Investment analysts at began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Down 3.3 %

Bellerophon Therapeutics stock opened at $1.18 on Friday. Bellerophon Therapeutics has a 52 week low of $0.67 and a 52 week high of $4.49. The company’s 50 day moving average price is $1.36 and its two-hundred day moving average price is $1.44. The stock has a market cap of $11.26 million, a P/E ratio of -0.60 and a beta of -0.07.

Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) last posted its earnings results on Monday, August 15th. The biotechnology company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.18. On average, equities analysts anticipate that Bellerophon Therapeutics will post -2.21 EPS for the current year.

Institutional Investors Weigh In On Bellerophon Therapeutics

An institutional investor recently raised its position in Bellerophon Therapeutics stock. Renaissance Technologies LLC lifted its stake in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) by 13.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 209,399 shares of the biotechnology company’s stock after purchasing an additional 24,100 shares during the period. Renaissance Technologies LLC owned 2.19% of Bellerophon Therapeutics worth $258,000 at the end of the most recent quarter. Institutional investors own 11.92% of the company’s stock.

Bellerophon Therapeutics Company Profile

(Get Rating)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Featured Stories

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.